It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Ovarian cancer has the highest mortality rate among gynecologic tumors, with a 5-year survival rate of less than 25%. There is an urgent need for early diagnosis and new drugs to reduce the disease burden of ovarian cancer. The aim of this study was to investigate the effectiveness of SLC11A2 as a therapeutic target and marker for ovarian cancer. Expression data of SLC11A2 were obtained from public databases. Then, the biological functions of SLC11A2 were validated in four ovarian cancer cell lines. Finally, we collected ovarian cancer clinical tissues, serum, and plasma exosomes and used immunohistochemistry, Elisa, and liquid chromatography-mass spectrometry (LC–MS) to validate the test efficacy of SLC11A2. The results showed that ovarian cancers with high SLC11A2 mRNA expression had shorter 5-year PFS and MST. Knockdown of SLC11A2 reduced ovarian cancer migration and increased cisplatin-induced apoptosis. Serum SLC11A2 may help improve the detection rate of ovarian cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The First Affiliated Hospital, Sun Yat-Sen University, Department of Gynecology, Guangzhou, China (GRID:grid.412615.5) (ISNI:0000 0004 1803 6239); Qilu Hospital of Shandong University (Qingdao), Department of Gynecology, Jinan, China (GRID:grid.452402.5) (ISNI:0000 0004 1808 3430)
2 School of Medicine, Xiamen University, Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen Key Laboratory of Genetic Testing, Xiamen, China (GRID:grid.12955.3a) (ISNI:0000 0001 2264 7233)
3 The First Affiliated Hospital, Sun Yat-Sen University, Department of Gynecology, Guangzhou, China (GRID:grid.412615.5) (ISNI:0000 0004 1803 6239); The Sixth Affiliated Hospital, Sun Yat-Sen University, Department of Gynecology, Guangzhou, China (GRID:grid.488525.6)
4 The First Affiliated Hospital, Sun Yat-Sen University, Department of Gynecology, Guangzhou, China (GRID:grid.412615.5) (ISNI:0000 0004 1803 6239)
5 The First Affiliated Hospital, Sun Yat-Sen University, Department of Radiotherapy, Guangzhou, China (GRID:grid.412615.5) (ISNI:0000 0004 1803 6239)